CClinicalTrials.gg
RecruitingNCT07683962EWH_regUpdated Jul 31, 2026

Influence of Early Wound Healing on the Outcomes of Regenerative Periodontal Surgery

An observational study in Intrabony Periodontal Defect and Wound Healing, sponsored by University of Roma La Sapienza. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by University of Roma La Sapienza · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates whether early post-surgical healing (1-2 weeks) affects the 12-month clinical and radiographic success of periodontal regenerative therapy, and identifies patient-related, site-specific, and technique-related factors associated with optimal early wound healing, in patients with Stage III-IV periodontitis.

Read the detailed description

This single-center, prospective observational cohort study addresses two pre-specified aims: (1) the association between early wound healing at 1 and 2 weeks and 12-month clinical and radiographic outcomes; and (2) the identification of patient-related, site-related (e.g., intrabony defect depth, CEJ-to-bone-crest distance, defect configuration, intrabony defect classification), and technique-related (flap design, biomaterial) factors associated with optimal early wound healing.

02

Conditions studied

  • Intrabony Periodontal Defect
  • Wound Healing

Keywords

  • periodontal regeneration
  • early wound healing
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients (age >=18) diagnosed with Stage III or IV Periodontitis according to the 2017 World Workshop Classification. These patients present with at least one deep interproximal infrabony defect requiring regenerative surgical treatment. Participants are recruited from the patient pool of the Section of Periodontics at Sapienza University of Rome, Italy. The population includes both systemically healthy individuals and those with well-controlled systemic conditions (ASA I or II), who have maintained optimal oral hygiene (FMPS/FMBS \< 15%) following initial non-surgical periodontal therapy.

Inclusion criteria

  • Diagnosis of Stage III or IV Periodontitis.
  • Presence of at least one deep interproximal infrabony defect (Probing Pocket Depth [PPD] >= 6 mm, radiographic depth >= 3 mm).
  • Optimal oral hygiene: Full-Mouth Plaque Score (FMPS) and Full-Mouth Bleeding Score (FMBS) \< 15% at the time of surgery.

Exclusion criteria

Exclusion Criteria:

  • Systemic: ASA III-VI classification; uncontrolled diabetes; medications causing gingival overgrowth (e.g., nifedipine, cyclosporine, phenytoin); heavy smokers (>10 cigarettes/day); pregnancy or lactation.
  • Local: Third molars; Grade III tooth mobility; inadequate endodontic treatment; teeth undergoing orthodontic treatment; teeth supporting removable or implant-linked fixed prosthetics.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Periodontal Regeneration Cohort

    This single cohort consists of patients with Stage III-IV periodontitis presenting at least one deep vertical infrabony defect. All patients receive periodontal regenerative surgery according to clinical indications. The cohort will be subsequently stratified into subgroups during data analysis based on the early wound healing assessment at 1 and 2 weeks to evaluate the impact of healing quality on 12-month clinical attachment level (CAL) and radiographic outcomes and to identify patient-related, site-specific, and/or technique-related factors associated with optimal early wound healing,

    Procedure: Periodontal Regenerative Therapy

Interventions

  • ProcedurePeriodontal Regenerative Therapy

    All subjects undergo surgical debridement of the intrabony defect followed by a regenerative approach (biologics with or without bone grafts, or blood clot alone) using papilla preservation techniques (MIST, M-MIST, MPPT, SPPF, or SFA).

05

What researchers measure

Primary outcomes

  1. Change in Clinical Attachment Level (CAL).

    Time frame: Baseline and 12 months.

Secondary outcomes

  1. Composite healing index (CHI)

    CHI has two independent, dichotomous domains (wound closure and wound quality), each answering a single clinically distinct question, and reports the outcome as a two-digit composite code.

    Time frame: 1 and 2 weeks

  2. Probing Pocket Depth (PPD) Change:

    Time frame: Baseline and 12 months.

  3. Early Wound Healing Index (EHI)

    Assessed using the Early Wound Healing Index (EHI). The index ranges from a minimum score of 1 (complete tissue closure without fibrin) to a maximum score of 5 (incomplete tissue closure with partial/complete necrosis). Higher scores mean a worse clinical outcome.

    Time frame: 1 and 2 weeks

  4. Change in Radiographic Parameters

    Measured in millimeters (mm) or degrees (°) on standardized radiographs from baseline to 12 months. It calculates the distance from a fixed reference point (e.g., cementoenamel junction) to the bottom of the bony defect. A positive change (increase in mm) indicates bone gain (better outcome).

    Time frame: Baseline and 12 months.

  5. Number of analgesic tablets

    Time frame: 1 and 2 weeks

  6. Percentage of Sites With Bleeding on Probing (BOP)

    Presence or absence of bleeding assessed within 30 seconds of probing at specific sites. The data will be aggregated and reported as the percentage of sites showing bleeding out of the total sites examined. Higher percentages indicate worse outcomes.

    Time frame: Baseline and 12 months

  7. Composite outcome measure (COM)

    Proportion of sites achieving a combination of PPD ≤ 4 mm and CAL gain ≥ 3 mm

    Time frame: 12 months

  8. Pocket closure

    Proportion of sites achieving a combination of PPD ≤ 4 mm and absence of bleeding on probing

    Time frame: 12 months

06

Study locations

1 of 1 sites recruiting
  • Sapienza University of Rome, Department of Oral and Maxillofacial Sciences, Section of Periodontology
    Rome, Rome 00161, Italy
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07683962
Lead sponsor
University of Roma La Sapienza
Responsible party
Andrea Pilloni MD DDS MS (Professor, University of Roma La Sapienza) — Principal investigator
First posted
Jul 6, 2026
Start date
Jul 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 31, 2026

Study contacts

Andrea Pilloni
Contact
andrea.pilloni@uniroma1.it
+39 3356409374

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion